[
  {
    "ts": null,
    "headline": "Incyte (INCY): Evaluating Valuation as Baricitinib Advances Toward Expanded Approval for Adolescent Alopecia Areata",
    "summary": "New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results. See our latest analysis for Incyte. Incyte’s momentum has really picked up this year thanks to positive trial results and recent pipeline updates, such as its advances in atopic dermatitis and cancer immunotherapies. The stock’s strong 31% share price...",
    "url": "https://finnhub.io/api/news?id=4ddc785d716799a213a367042dd19d521b9065fe6415776bfb882123be484b0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761501990,
      "headline": "Incyte (INCY): Evaluating Valuation as Baricitinib Advances Toward Expanded Approval for Adolescent Alopecia Areata",
      "id": 137215914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results. See our latest analysis for Incyte. Incyte’s momentum has really picked up this year thanks to positive trial results and recent pipeline updates, such as its advances in atopic dermatitis and cancer immunotherapies. The stock’s strong 31% share price...",
      "url": "https://finnhub.io/api/news?id=4ddc785d716799a213a367042dd19d521b9065fe6415776bfb882123be484b0e"
    }
  }
]